SIBN SI-BONE

SI-BONE Reports Preliminary Unaudited Revenue for the Third Quarter 2020 and Provides Full Year 2020 Revenue Guidance

SI-BONE Reports Preliminary Unaudited Revenue for the Third Quarter 2020 and Provides Full Year 2020 Revenue Guidance
EN
08/10/2020

Underlying

SIBNSI-BONE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SI-BONE

 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and...

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter Third Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.7 million, representing growth of 20.6%  U.S. revenue of $46.4 million, representing growth of 21.2%Gross margin of 79.8%, representing an improvement of 75 basis pointsNet loss of $4.6 million, representing an improvement of 30.6%  Positive adjusted EBITDA of $...

November 10, 2025 1 EN
 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE To Report Third Quarter 2025 Financial Results on November 10,...

SI-BONE To Report Third Quarter 2025 Financial Results on November 10, 2025 SANTA CLARA, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2025 after market close on Monday, November 10, 2025. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: Live audio of the webcast will be avai...

October 20, 2025 1 EN
 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference...

SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025 SANTA CLARA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Management will be hosting a fireside chat on Tuesday, September 9, 2025, at 4:00 a.m. Pacific Time/ 07:00 a.m. Eastern Time. Investors interested in listening to the conference call may do so by register...

August 26, 2025 1 EN
 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 an...

SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven Second Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $48.6 million, representing growth of 21.7%U.S. revenue of $46.4 million, representing growth of 22.8%Gross margin of 79.8%, representing an improvement of 80 basis pointsNet loss of $6.2 million, representing an improvement of 31.2%Positive adjusted EBITDA of $1.0 million$145.5 million in cash and equ...

August 4, 2025 1 EN
 PRESS RELEASE
Free
SIBN SI-BONE

SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference ...

SI-BONE To Present at Canaccord Genuity 45th Annual Growth Conference on August 12, 2025 SANTA CLARA, Calif., July 29, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Canaccord Genuity 45th Annual Growth Conference in Boston, MA. Management will be hosting a fireside chat on Tuesday, August 12, 2025, at 12:00 p.m. Pacific Time/03:00 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this lin...

July 29, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch